Podcast: How to invest in medical cannabis legally from Europe
THE CANNABIS CONVERSATION PODCAST – How to invest in medical cannabis legally from Europe
In this podcast, we join Anuj Desai, Founder of The Cannabis Conversation, to dispel all confusion around investing in medical cannabis companies from Europe. We explain how our investment policy, through the establishment of our Two-Tiered Due Diligence Process, ensures compliance with the UK’s Proceeds of Crime Act 2002 and the UK’s Misuse of Drugs Act 1971. The Rize Medical Cannabis and Life Sciences UCITS ETF is currently authorised by the Central Bank of Ireland, registered with the UK Financial Conduct Authority and trading on the London Stock Exchange.
Recorded on April 14th, 2020.
FLWR: The Rize Medical Cannabis and Life Sciences UCITS ETF seeks to track the Foxberry Medical Cannabis & Life Sciences Index. The objective of the Index is to provide exposure to companies involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. The Index excludes companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market.
Capital at Risk Warning: An investment in the Fund(s) involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. The Funds may be registered or otherwise approved for distribution to the public in one or more European jurisdictions. Investors should continue to consider the terms of investment in any Fund (or Share Class thereof) carefully and seek professional investment advice before taking any decision to invest in such Fund (or Share Class thereof).